Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
